LATAM Uterine Cancer Market Size & Outlook, 2025-2033


LATAM Uterine Cancer Market Insights

  • As highlighted in Reed Intelligence analysis, the LATAM Uterine Cancer Market, valued at USD 488.91 Million in 2024, is estimated to achieve USD 766.91 Million by 2033.
  • The market is estimated to grow at a CAGR of 5.11% spanning 2026 to 2033.
  • By market size, Endometrial Adenocarcinoma led the By Type category in 2024.
  • The By Type segment led by Endometrial Adenocarcinoma is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.

Other Key Findings


  • The global Uterine Cancer Market size saw LATAM holding a share of 7.81% in 2024.
  • United States is forecasted to account for the leading share of the global market by 2033.
  • In LATAM, Argentina is forecasted to be the fastest-expanding market, projected to reach USD 78.16 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 488.91 Million
Market Size In 2033 USD 766.91 Million
Largest segment Endometrial Adenocarcinoma
Units Revenue in USD Million
CAGR 5.11% (2025-2033)
Segmnetation Covered
LATAM
  1. Brazil
  2. Mexico
  3. Argentina
  4. Colombia
  5. Chile
By Type
  1. Endometrial Adenocarcinoma
  2. Adenosquamous Carcinoma
  3. Papillary Serous Carcinoma
  4. Uterine Sarcoma
By Treatment
  1. Diagnosis
  2. Therapeutic Treatment
  3. Surgery
By End-Users
  1. Hospitals
  2. Diagnostic Centers
  3. Drug Stores
  4. Online Pharmacies
  5. Other End Users
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends